Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

798dbd1d-9df6-42ab-8fe9-c48e416b3ec1

—

6b2a1a57-ef5a-53c8-9712-d33bca196ad1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
age_years
68

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.490
  • E2F_TARGETS+0.370
  • INTERFERON_GAMMA_RESPONSE+0.370
  • G2M_CHECKPOINT+0.340
  • APICAL_SURFACE+0.300
  • GLYCOLYSIS+0.210
  • NOTCH_SIGNALING+0.210
  • SPERMATOGENESIS+0.200
  • MITOTIC_SPINDLE+0.180
  • IL6_JAK_STAT3_SIGNALING+0.160

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.360
  • MYC_TARGETS_V1-0.300
  • CHOLESTEROL_HOMEOSTASIS-0.290
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
  • UNFOLDED_PROTEIN_RESPONSE-0.280
  • PANCREAS_BETA_CELLS-0.220
  • TGF_BETA_SIGNALING-0.210
  • WNT_BETA_CATENIN_SIGNALING-0.200
  • DNA_REPAIR-0.180
  • P53_PATHWAY-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR4296066
lung-landscapes@6
—cohortA10.667
2SRR650133
bladder-landscape@3
——0.664
3BS_M15PW2N0
medullo-epn-umap@date-based
MedMedulloblastoma0.656
469201842-6398-4509-b227-fca5bc12b08d
colon-landscapes@1
——0.650
5TCGA-A7-A2KD-01A-31R-A21T-07
breast-umap@18
—C0.635
6TCGA-62-8394-01A-11R-2326-07
lung-landscapes@6
—cohortA10.631
7MDT-AP-1349
medullo-epn-umap@date-based
MedMedulloblastoma0.627
8SRR6079981
head-neck@1
——0.625
9MNG821
mng-umap@100
——0.621
10MDT-AP-2863
medullo-epn-umap@date-based
MedMedulloblastoma0.621

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.490Inavolisib— uncovered
E2F_TARGETS0.370Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.370Idelalisib— uncovered
G2M_CHECKPOINT0.340Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
GLYCOLYSIS0.210Inavolisib— uncovered
NOTCH_SIGNALING0.210Inavolisib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.160Inavolisib— uncovered
ANGIOGENESIS0.150Remibrutinib— uncovered
PEROXISOME0.140Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.110Idelalisib— uncovered
COAGULATION0.090Binimetinib— uncovered
UV_RESPONSE_DN0.080Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.070Inavolisib— uncovered
APICAL_JUNCTION0.060Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.060Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.060Inavolisib— uncovered
KRAS_SIGNALING_UP0.060Inavolisib— uncovered